Immunizing children and adolescents with inactivated<sup> </sup>influenza vaccine significantly protected unimmunized residents<sup> </sup>of rural communities against influenza.
Effect of Influenza Vaccination of Children on Infection Rates in Hutterite Communities
free full text
abstract
Context Children and adolescents appear to play an important<sup> </sup>role in the transmission of influenza. Selectively vaccinating<sup> </sup>youngsters against influenza may interrupt virus transmission<sup> </sup>and protect those not immunized.<sup> </sup> Objective To assess whether vaccinating children and adolescents<sup> </sup>with inactivated influenza vaccine could prevent influenza in<sup> </sup>other community members.<sup> </sup>
Design, Setting, and Participants A cluster randomized<sup> </sup>trial involving 947 Canadian children and adolescents aged 36<sup> </sup>months to 15 years who received study vaccine and 2326 community<sup> </sup>members who did not receive the study vaccine in 49 Hutterite<sup> </sup>colonies in Alberta, Saskatchewan, and Manitoba. Follow-up began<sup> </sup>December 28, 2008, and ended June 23, 2009.<sup> </sup>
Intervention Children were randomly assigned according<sup> </sup>to community and in a blinded manner to receive standard dosing<sup> </sup>of either inactivated trivalent influenza vaccine or hepatitis<sup> </sup>A vaccine, which was used as a control.<sup> </sup>
Main Outcome Measures Confirmed influenza A and B infection<sup> </sup>using a real-time reverse transcriptase polymerase chain reaction<sup> </sup>(RT-PCR) assay and by measuring serum hemagglutination inhibition<sup> </sup>titers.<sup> </sup>
Results The mean rate of study vaccine coverage among<sup> </sup>eligible participants was 83% (range, 53%-100%) for the influenza<sup> </sup>vaccine colonies and 79% (range, 50%-100%) for the hepatitis<sup> </sup>A vaccine colonies. Among nonrecipients, 39 of 1271 (3.1%) in<sup> </sup>the influenza vaccine colonies and 80 of 1055 (7.6%) in the<sup> </sup>hepatitis A vaccine colonies had influenza illness confirmed<sup> </sup>by RT-PCR, for a protective effectiveness of 61% (95% confidence<sup> </sup>interval [CI], 8%-83%; P = .03). Among all study participants<sup> </sup>(those who were and those who were not vaccinated), 80 of 1773<sup> </sup>(4.5%) in the influenza vaccine colonies and 159 of 1500 (10.6%)<sup> </sup>in the hepatitis A vaccine colonies had influenza illness confirmed<sup> </sup>by RT-PCR for an overall protective effectiveness of 59% (95%<sup> </sup>CI, 5%-82%; P = .04). No serious vaccine adverse events<sup> </sup>were observed.<sup> </sup>
Conclusion Immunizing children and adolescents with inactivated<sup> </sup>influenza vaccine significantly protected unimmunized residents<sup> </sup>of rural communities against influenza.<sup> </sup>
Trial Registration clinicaltrials.gov Identifier: NCT00877396
Effect of Influenza Vaccination of Children on Infection Rates in Hutterite Communities
free full text
abstract
Context Children and adolescents appear to play an important<sup> </sup>role in the transmission of influenza. Selectively vaccinating<sup> </sup>youngsters against influenza may interrupt virus transmission<sup> </sup>and protect those not immunized.<sup> </sup> Objective To assess whether vaccinating children and adolescents<sup> </sup>with inactivated influenza vaccine could prevent influenza in<sup> </sup>other community members.<sup> </sup>
Design, Setting, and Participants A cluster randomized<sup> </sup>trial involving 947 Canadian children and adolescents aged 36<sup> </sup>months to 15 years who received study vaccine and 2326 community<sup> </sup>members who did not receive the study vaccine in 49 Hutterite<sup> </sup>colonies in Alberta, Saskatchewan, and Manitoba. Follow-up began<sup> </sup>December 28, 2008, and ended June 23, 2009.<sup> </sup>
Intervention Children were randomly assigned according<sup> </sup>to community and in a blinded manner to receive standard dosing<sup> </sup>of either inactivated trivalent influenza vaccine or hepatitis<sup> </sup>A vaccine, which was used as a control.<sup> </sup>
Main Outcome Measures Confirmed influenza A and B infection<sup> </sup>using a real-time reverse transcriptase polymerase chain reaction<sup> </sup>(RT-PCR) assay and by measuring serum hemagglutination inhibition<sup> </sup>titers.<sup> </sup>
Results The mean rate of study vaccine coverage among<sup> </sup>eligible participants was 83% (range, 53%-100%) for the influenza<sup> </sup>vaccine colonies and 79% (range, 50%-100%) for the hepatitis<sup> </sup>A vaccine colonies. Among nonrecipients, 39 of 1271 (3.1%) in<sup> </sup>the influenza vaccine colonies and 80 of 1055 (7.6%) in the<sup> </sup>hepatitis A vaccine colonies had influenza illness confirmed<sup> </sup>by RT-PCR, for a protective effectiveness of 61% (95% confidence<sup> </sup>interval [CI], 8%-83%; P = .03). Among all study participants<sup> </sup>(those who were and those who were not vaccinated), 80 of 1773<sup> </sup>(4.5%) in the influenza vaccine colonies and 159 of 1500 (10.6%)<sup> </sup>in the hepatitis A vaccine colonies had influenza illness confirmed<sup> </sup>by RT-PCR for an overall protective effectiveness of 59% (95%<sup> </sup>CI, 5%-82%; P = .04). No serious vaccine adverse events<sup> </sup>were observed.<sup> </sup>
Conclusion Immunizing children and adolescents with inactivated<sup> </sup>influenza vaccine significantly protected unimmunized residents<sup> </sup>of rural communities against influenza.<sup> </sup>
Trial Registration clinicaltrials.gov Identifier: NCT00877396
Comment